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The in vitro activities of the new biguanide PS-15 and its putative active metabolite, WR99210, were
determined against seven different isolates or clones of Plasmodium falciparum. The mean 50% inhibitory
concentrations of PS-15 and WR99210 were 1,015 and 0.06 ng/ml, respectively. WR99210 was up to 363 times
more potent than cycloguanil, the active metabolite of proguanil, against cycloguanil-resistant parasites. The
pronounced activity of WR99210 against multidrug-resistant P. falciparum indicates that further studies are
required to determine the value of the prodrug, PS-15, as an antimalarial agent.
Plasmodium falciparum resistance to chloroquine and the
antifolate drugs pyrimethamine-sulfadoxine (Fansidar) and
proguanil is widespread in Southeast Asia (4, 9). In Thailand,
resistance to mefloquine has developed rapidly over the last
decade. New antimalarial drugs are urgently needed both for
treatment and for prophylaxis. Recently, a biguanide related to
proguanil, designated PS-15 [also known as WR250417; N-3-
(2,4,5-trichlorophenoxypropyloxy)-N9-(1-methyl-ethyl)imido-
carbonimidic diamide], was developed as a potentially new
antimalarial drug (2). PS-15 is metabolized to its putative ac-
tive metabolite, WR99210 [also known as BRL6231; 4,6-dia-
mino-1,2-dihydro-2,2-dimethyl-1-(2,4,5-trichlorophenoxypro-
pyloxy)-1,3,5-triazine], a structural analog of cycloguanil, the
active metabolite of proguanil.
In 1973, Rieckmann (12) demonstrated the potent in vitro
antimalarial activity of WR99210 against the highly chloro-
quine- and pyrimethamine-resistant strain Viet-Nam (Marks).
The potency of WR99210, its lack of in vivo cross-resistance
with chloroquine, pyrimethamine, and cycloguanil (6), and the
relative difficulty of inducing resistance to the triazine in Plas-
modium berghei-infected mice (7) led to clinical trials with
WR99210. Oral administration of this compound was associ-
ated with gastrointestinal intolerance, possibly due to poor
drug absorption (1). Nevertheless, because of the significant
antimalarial activity of WR99210, it provided the impetus for
the synthesis of the prodrug PS-15, which was designed to
circumvent the toxic effects and limited bioavailability of
WR99210 (2).
Studies with PS-15 with eight Saimiri monkeys indicated that
the prodrug is readily metabolized to WR99210 (13). None of
the monkeys developed diarrhea or other observable side ef-
fects. The similar concentrations of WR99210 in serum ob-
tained by bioassay and high-performance liquid chromato-
graphic analysis, coupled with the far greater susceptibility of
parasites to WR99210 than to PS-15 in vitro, indicated that the
metabolite was responsible for most of the antimalarial activity
observed in vivo after administration of PS-15. These investi-
gations also demonstrated that the antimalarial activity in se-
rum was 20 to 86 times higher in monkeys receiving PS-15 than
in those receiving WR99210, indicating that the prodrug was
absorbed much better from the gastrointestinal tract than
WR99210.
Although WR99210 has been shown to have potent in vitro
activity against different strains of P. falciparum, previous stud-
ies were carried out with a limited number of isolates or clones
(2, 12) or in culture medium not suitable for the assessment of
antifolates (3). The aim of this study was to assess the intrinsic
in vitro activities of PS-15 and WR99210 in folate and para-
aminobenzoic acid (PABA)-free medium and to compare their
activities with those of proguanil and cycloguanil against a
larger number of Thai isolates or clones of P. falciparum with
diverse levels of resistance to cycloguanil, pyrimethamine, and
dapsone.
Six culture-adapted isolates or clones of P. falciparum from
Thailand were used in the study, and their activities were
compared to that of the drug-sensitive D6 clone (11). The
chloroquine- and pyrimethamine-resistant K1 isolate (15) and
the chloroquine- and mefloquine-resistant CH12 isolate (16)
had been in culture for at least 10 years. The other four isolates
or clones had been adapted to culture more recently. The GA3
clone was obtained from a malaria-infected Thai patient who
had failed sulfadoxine, pyrimethamine, and mefloquine (Fan-
simef) treatment (7a). Isolates PD-234, PD-701, and PD-728
were obtained from malaria-infected Thai soldiers who were
not protected by daily proguanil-dapsone prophylaxis (14).
PS-15 hydrochloride, WR99210 hydrochloride, dapsone, and
pyrimethamine were kindly supplied by Jacobus Pharmaceuti-
cal Company (Princeton, N.J.). Proguanil hydrochloride and
cycloguanil were supplied by ICI Pharmaceuticals (Maccles-
field, United Kingdom). The susceptibility of each isolate or
clone to the antifolates was determined by the radioisotopic
method of Milhous et al. (10), with minor modifications. Par-
asites were synchronized repeatedly with 5% sorbitol to pro-
duce experimental cultures consisting predominantly of para-
sites 6 to 12 h into the cycle (8). The parasite suspension (225
ml/well) consisted of infected erythrocytes (1.5% hematocrit,
0.3 to 0.5% parasitemia) in folate and PABA-free RPMI 1640
medium (GIBCO, Grand Island, N.Y.) supplemented with
10% human serum, 25 mmol of HEPES (N-2-hydroxyeth-
ylpiperazine-N9-2-ethanesulfonic acid) buffer per liter, 25
mmol of NaHCO3 per liter, and gentamicin (25 mg per liter).
The microculture plates were initially incubated for 48 h at
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37.5°C in a gas mixture of 5% O2–5% CO2–90% N2 to allow
for merozoite reinvasion of the erythrocytes. [3H]hypoxanthine
(25 ml containing 0.5 mCi) was then added to each well. After
a further 18 h of incubation, the cells were harvested to mea-
sure the level of incorporation of [3H]hypoxanthine as an index
of parasite growth inhibition. The 50% inhibitory concentra-
tion (IC50) was defined as the drug concentration that inhibits
50% of isotope incorporation by the parasites relative to the
level of incorporation by parasites in drug-free control wells.
The concentration-response data were analyzed by linear re-
gression analysis. Each test was repeated at least three times.
The in vitro activities of PS-15, proguanil, cycloguanil,
WR99210, pyrimethamine, and dapsone against isolates or
clones of P. falciparum are given in Table 1. PS-15 showed poor
antimalarial activity against the D6 and GA3 clones and the K1
and CH12 isolates and was not appreciably more active than
proguanil. WR99210 was more than 1,000 times more active
than PS-15 and was also 46 to 363 times more active than
cycloguanil against all isolates or clones except the cycloguanil-
sensitive D6 clone. Noteworthy was the marked activity of
WR99210 against the three isolates obtained from the malaria-
infected Thai soldiers while on proguanil-dapsone prophylaxis.
Our findings indicate that WR99210 is remarkably active
against older and newer parasite isolates from Thailand, where
current antimalarial agents are often no longer effective
against falciparum malaria. The lack of cross-resistance with
cycloguanil and pyrimethamine suggests that the mechanism of
action of WR99210 differs from those of other antifolates. The
data support those obtained with old clones or isolates from
other countries (2, 12) where parasites generally remain more
susceptible to antimalarial drugs than in Thailand.
No definitive toxicity studies have yet been carried out with
PS-15. However, drug-induced toxicity was not seen in rodents
(5) or Saimiri monkeys given PS-15 (13). If humans are able to
tolerate, absorb, and metabolize PS-15, the substantial in vitro
activity of WR99210 against multidrug-resistant P. falciparum
suggests that PS-15 is a prime candidate for further develop-
ment as an antimalarial drug.
We thank Kyle Webster and Dennis Kyle for providing clones D6
and GA3 and the CH12 isolate.
This paper is published with the permission of the Director General
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TABLE 1. In vitro antimalarial activities of PS-15, proguanil, cycloguanil, WR99210, pyrimethamine, and dapsone against P. falciparum
isolates or clones cultured in folate and PABA-free RPMI 1640 medium
Isolate or
clone
IC50 (ng/ml) of the following antifolatesa: Ratio of IC50 of
CYC to IC50 of
WR99210PS-15 PROG CYC WR99210 PYR DDS
D6 70 6 22 219 6 39 0.06 6 0.02 0.06 6 0.06 0.06 6 0.02 3.1 6 1.2 2.3
K1 3,133 6 1,465 3,786 6 1,869 5.5 6 1.4 0.12 6 0.02 178 6 36 11.0 6 2.8 46
CH12 326 6 82 608 6 143 10.9 6 1.5 0.05 6 0.01 177 6 20 13.0 6 4.1 218
GA3 532 6 122 844 6 252 0.94 6 0.38 0.02 6 0.01 36.2 6 12.1 195 6 48 47
PD-234b ND ND 17.6 6 7.8 0.06 6 0.04 0.47 6 0.23 1.6 6 0.7 293
PD-701b ND ND 14.5 6 2.7 0.04 6 0.02 0.35 6 0.08 1.3 6 0.4 363
PD-728b ND ND 14.8 6 7.0 0.07 6 0.03 0.45 6 0.27 2.8 6 2.0 211
a PROG, proguanil; CYC, cycloguanil; PYR, pyrimethamine; DDS, dapsone; ND, not determined. Mean 6 standard deviation IC50 vs are based on the results of
three or more experiments.
b Isolates of P. falciparum obtained from Thai soldiers while on proguanil-dapsone prophylaxis.
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